Kavar Capital Partners Group, LLC Gilead Sciences, Inc. Transaction History

Kavar Capital Partners Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$57.92 - $72.58 $169,705 - $212,659	-2,930 Closed	0 $0
Q4 2021 Jan 27, 2022	SELL	$64.88 - $73.64 $1.17 Million - $1.33 Million	-17,995 Reduced 86.0%	2,930 $213,000
Q3 2021 Nov 01, 2021	SELL	$67.69 - $73.03 $16,922 - $18,257	-250 Reduced 1.18%	20,925 $1.46 Million
Q2 2021 Aug 02, 2021	SELL	$63.47 - $69.35 $75,529 - $82,526	-1,190 Reduced 5.32%	21,175 $1.46 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $31,500 - $35,941	-525 Reduced 2.29%	22,365 $1.45 Million
Q4 2020 Feb 05, 2021	BUY	$56.65 - $64.55 $1.3 Million - $1.48 Million	22,890 New	22,890 $1.33 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Kavar Capital Partners Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Kavar Capital Partners Group, LLC with notifications on news.